Acute kidney injury (AKI) was defined as occurring in the first 7 days after birth, and caffeine citrate administration was defined as occurring before an AKI event. AWAKEN indicates Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates; GA, gestational age; IV, intravenous; SCr, serum creatinine; and UOP, urine output.
aBecause exclusion criteria are not mutually exclusive, some potential participants could have been excluded for multiple reasons and are counted in each exclusion category.
eTable 1. Comparison by Caffeine Status on Day 1
eTable 2. Comparison by Caffeine Status on Day 1 and 2
eTable 3. Clinical Characteristics by AKI Diagnosis
eTable 4. Extremely Preterm (<28 Weeks’ Gestation) Demographics
eTable 5. Very Preterm (28-32 6/7 Weeks’ Gestation) Demographics
eFigure. Kaplan-Meier AKI-Free Survival Curve
Customize your JAMA Network experience by selecting one or more topics from the list below.
Harer MW, Askenazi DJ, Boohaker LJ, et al. Association Between Early Caffeine Citrate Administration and Risk of Acute Kidney Injury in Preterm Neonates: Results From the AWAKEN Study. JAMA Pediatr. 2018;172(6):e180322. doi:10.1001/jamapediatrics.2018.0322
Is early caffeine citrate administration associated with reduced incidence or severity of acute kidney injury in preterm neonates?
In this multicenter cohort study of 675 preterm neonates, those who received caffeine in the first 7 days after birth developed acute kidney injury less frequently than neonates who did not (11.2% vs 31.6%).
Caffeine administration in the first 7 days after birth may be associated with less frequent acute kidney injury in preterm neonates; further studies on dosage, the timing of administration, and long-term outcomes are needed.
Acute kidney injury (AKI) occurs commonly in preterm neonates and is associated with increased morbidity and mortality.
To examine the association between caffeine citrate administration and AKI in preterm neonates in the first 7 days after birth and to test the hypothesis that caffeine administration would be associated with reduced incidence and severity of AKI.
Design, Setting, and Participants
This study was a secondary analysis of the Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study, a retrospective observational cohort that enrolled neonates born from January 1 to March 31, 2014. The dates of analysis were October 2016 to December 2017. The setting was an international, multicenter cohort study of neonates admitted to 24 participating level III or IV neonatal intensive care units. Participants met the original inclusion and exclusion criteria of the AWAKEN study. Additional exclusion criteria for this study included participants greater than or equal to 33 weeks’ gestation at birth, admission after age 7 days, use of theophylline in the neonatal intensive care unit, or lack of data to define AKI. There were 675 preterm neonates available for analysis.
Administration of caffeine in the first 7 days after birth.
Main Outcomes and Measures
The primary outcome was the incidence of AKI (based on the modified neonatal Kidney Disease: Improving Global Outcomes [KDIGO] definition) in the first 7 days after birth. The hypothesis that caffeine administration would be associated with reduced AKI incidence was formulated before data analysis.
The study cohort (n = 675) was 55.4% (n = 374) male, with a mean (SD) gestational age of 28.9 (2.8) weeks and a mean (SD) birth weight of 1285 (477) g. Acute kidney injury occurred in 122 neonates (18.1%) in the first 7 days after birth. Acute kidney injury occurred less frequently among neonates who received caffeine than among those who did not (50 of 447 [11.2%] vs 72 of 228 [31.6%], P < .01). After multivariable adjustment, administration of caffeine remained associated with reduced odds of developing AKI (adjusted odds ratio, 0.20; 95% CI, 0.11-0.34), indicating that for every 4.3 neonates exposed to caffeine one case of AKI was prevented. Among neonates with early AKI, those receiving caffeine were less likely to develop stage 2 or 3 AKI (adjusted odds ratio, 0.20; 95% CI, 0.12-0.34).
Conclusions and Relevance
Caffeine administration in preterm neonates is associated with reduced incidence and severity of AKI. Further studies should focus on the timing and dosage of caffeine to optimize the prevention of AKI.
In recent decades, advances in the care of preterm neonates have dramatically lowered mortality rates.1-3 As survival has improved, clinicians have been increasingly focused on decreasing the short-term and long-term sequelae of prematurity.4 Acute kidney injury (AKI) occurs frequently in preterm neonates and is associated with increased morbidity and mortality.5-7 In 2014, the Neonatal Kidney Collaborative (NKC) initiated an international, multicenter (24 centers in 4 countries) study designed to evaluate the incidence, risk factors, and outcomes associated with neonatal AKI called the Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study.8 This study demonstrated that 30% of neonates admitted to a neonatal intensive care unit (NICU) developed AKI and that those with AKI had 4.8 times higher adjusted odds of mortality compared with neonates without AKI.9 However, there are few specific strategies to prevent or ameliorate AKI beyond supportive measures, such as avoidance of nephrotoxins and optimization of blood pressure and fluid balance.10-12 Therefore, identifying therapies to prevent or reduce the severity of AKI are of paramount importance.
Methylxanthines are adenosine antagonists that act via A1 and A2A receptors present in the brain, heart, blood vessels, respiratory system, gastrointestinal tract, and kidneys.13 The results of clinical trials using theophylline or aminophylline have suggested that methylxanthines prevent AKI or improve renal function in special populations of high-risk neonates and infants, including those with perinatal hypoxia/ischemia or prematurity and undergoing cardiac surgery.14-20 However, these medications are no longer widely used in the general neonatal population: a 2014 study21 found that caffeine citrate (another methylxanthine) accounted for 96% of methylxanthine use in 2010. Whether exposure to caffeine might be associated with decreased incidence of AKI was explored by a single-center retrospective study22 of very low-birth-weight (VLBW) neonates (birth weight, <1500 g). Although the results of this study suggested that early caffeine administration might prevent AKI, to date there has been no comprehensive multicenter evaluation of caffeine administration and its association with AKI in preterm neonates.
To address this knowledge gap, we performed a secondary analysis of preterm neonates born at less than 33 weeks’ gestation enrolled in the AWAKEN study. The aim of this analysis was to examine the association of caffeine administration with AKI in the first 7 days after birth. We hypothesized that neonates given caffeine would have reduced incidence and severity of AKI.
A comprehensive description of the NKC and the methods used to collect the data for the AWAKEN study8 has been published. The University of Alabama at Birmingham Institutional Review Board approved this collaborative study, and each participating center received approval from their respective institutional review boards.
The AWAKEN study was a retrospective observational cohort investigation that enrolled neonates born from January 1 to March 31, 2014. The dates of analysis were October 2016 to December 2017. The setting was an international, multicenter cohort study of neonates admitted to 24 participating level III or IV NICUs. Data were collected from the time of NICU admission until discharge, transfer, death, or 120 days after birth, whichever came first. Inclusion criteria for the AWAKEN study were admission to the NICU and administration of intravenous fluids for at least the first 48 hours after admission. The original exclusion criteria for the AWAKEN study were individuals with admission 14 days or longer after birth, those with congenital heart disease requiring repair less than 7 days after birth, infants with lethal chromosomal anomaly, and neonates with death within 48 hours after birth. Specific to the present study, the following additional exclusion criteria applied: gestational age at least 33 weeks, admission more than 7 days after birth, admission to a NICU that used theophylline rather than caffeine, less than 1 day of measured urine output (UOP) on days 2 to 7 after birth, and fewer than 2 serum creatinine (sCr) measurements (Figure). Analysis was limited to participants younger than 33 weeks’ gestation because few neonates with gestational age at least 33 weeks received caffeine (owing to the low incidence of apnea of prematurity in this group).
The primary outcome of interest was early AKI occurring in the first 7 days after birth. Neonatal AKI was defined by the modified neonatal Kidney Disease: Improving Global Outcomes (KDIGO) definition (Table 1).23 This is the consensus definition for neonatal AKI based on the recommendation of a recent National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases workshop.24 Secondary outcomes of interest were the severity of AKI, defined by modified neonatal KDIGO staging, and the incidence of AKI within the entire data collection period.
The exposure of interest was administration of caffeine before AKI. If administration of caffeine occurred in the first 7 days after birth but after AKI occurred, these neonates were considered not to have received caffeine.
To characterize the cohort and to assess potential confounders, both maternal and neonatal data were collected, including the following: maternal age, mode of delivery, outborn delivery, pregnancy medications, gestational age, birth weight, small for gestational age status, sex, resuscitation efforts, Apgar scores, admission diagnoses, ventilation, patent ductus arteriosus therapies, initial sCr values, type of center, and neonatal medications in the NICU. Similar to the classification of caffeine administration, exposure to other neonatal medications, including antimicrobials, diuretics, and vasopressors, was defined as administration of the medication before AKI. The updated Clinical Risk Index for Babies (CRIB II) score was used to assess the severity of illness on admission.25
Comparisons were made using the χ2 test for categorical variables and the Fisher exact test for continuous variables. All continuous variables were tested for normality using the Shapiro-Wilk test. For normally distributed continuous variables, the means (SDs) were reported and analyzed using the t test. For nonnormally distributed variables, the medians (interquartile ranges) were reported, and groups were compared using the Mann-Whitney test.
To evaluate the association between caffeine administration and AKI—both early (ie, in the first 7 days after birth) and within 120 days—a generalized linear mixed model using a logit link and binary distribution and a random intercept by study site (to account for possible clustering by study site) was used to calculate unadjusted odds ratios (ORs) and associated 95% CIs. Maternal, neonatal, and clinical characteristics with P < .20 in bivariate analysis were considered candidate variables for the final adjusted model. Using a backward selection process, multivariable models were generated that included only variables with P < .05 to create the most parsimonious model to estimate adjusted ORs. To assess possible effect modification by gestational age, an interaction between gestational age and caffeine administration was entered into the final adjusted model to examine whether the observed associations between caffeine administration and AKI differed statistically by gestational age. In secondary analyses, the incidence of AKI was compared between caffeine groups using a generalized linear mixed model with a logit link and binomial distribution, and AKI staging was compared between caffeine groups using a generalized linear mixed model with a cumulative logit link and multinomial distribution for both early AKI and AKI within 120 days. All regression models were adjusted for gestational age, sepsis evaluation, type of center, and antibiotic use.
The number needed to be exposed (NNE), corresponding to the number of patients who would need to be treated with caffeine to prevent one case of AKI after adjustment for confounding variables, was calculated from the adjusted OR obtained in logistic regression using statistical methods described previously.26 For all analyses, 2-sided P < .05 was considered statistically significant. All statistical analyses were performed centrally at the University of Alabama at Birmingham using a software program (SAS, version 9.4; SAS Institute Inc).
The AWAKEN study enrolled 2162 participants. After the application of the additional exclusion criteria for this study, 675 preterm neonates were eligible for our secondary analysis (Figure). Of the 675 participants, 447 (66.2%) received at least one dose of caffeine in the first 7 days after birth and before AKI. Of the 228 neonates considered to have received no caffeine, 199 received no caffeine at all in the first 7 days after birth, while 29 received caffeine after AKI. For neonates included in the study, 36.9% (249 of 675) received their first dose of caffeine on day 1 after birth, and 53.8% (363 of 675) received their first dose within the first 2 days after birth. Bivariate analyses were conducted to compare the severity of illness between those who received caffeine on day 1 or day 1 and day 2 with those who did not receive caffeine (eTable 1 and eTable 2 in the Supplement). Neonates who did not receive caffeine had older gestational age, higher birth weight, greater Apgar scores at 5 minutes, and lower CRIB II scores, suggesting that these neonates were not sicker than those who received caffeine.
Compared with neonates who did not receive caffeine, neonates who received caffeine had younger gestational age and lower birth weight (Table 2). In addition, these neonates were more likely to be intubated in the delivery room and had lower median Apgar scores at 1 minute and 5 minutes. On admission, those receiving caffeine were more likely to have a diagnosis of respiratory distress, undergo a sepsis evaluation, and receive either invasive or noninvasive respiratory support. Neonates receiving caffeine were more likely to be given a nephrotoxic antimicrobial agent and a nonsteroidal anti-inflammatory drug in the NICU.
Acute kidney injury occurred in the first 7 days after birth in 18.1% (122 of 675) of neonates. Demographics of participants with early AKI compared with those without AKI are listed in eTable 3 in the Supplement. Neonates who received caffeine were less likely to develop early AKI compared with those who did not (11.2% [50 of 447] vs 31.6% [72 of 228], P < .01; unadjusted OR, 0.28; 95% CI, 0.18-0.44) (Table 3). The eFigure in the Supplement shows a Kaplan-Meier AKI-free survival curve for neonates in the first 7 days after birth. After multivariable analysis (adjusting for gestational age, sepsis evaluation, type of center, and nephrotoxic antimicrobial use), neonates who received caffeine remained less likely to have AKI than those who did not receive caffeine (adjusted OR, 0.20; 95% CI, 0.11-0.34; P < .001). The NNE to prevent a single case of AKI was 4.3.
Neonates who received caffeine were less likely to develop early AKI based on sCr values alone (adjusted OR, 0.20; 95% CI, 0.11-0.37); however, there was no association of use of caffeine with early AKI as defined by decreased UOP without a rise in creatinine (adjusted OR, 0.40; 95% CI, 0.15-1.06) (Table 4). Among neonates who developed early AKI, those receiving caffeine had an 80% decrease in the odds of stage 2 or 3 AKI (adjusted OR, 0.20; 95% CI, 0.12-0.34). Stage 3 AKI occurred approximately 8 times more frequently among neonates who did not receive caffeine (1.3% [6 of 447] vs 10.5% [24 of 228], P < .001).
Similar associations were observed for AKI that occurred after the initial 7 days (before NICU discharge, transfer, death, or age 120 days). The incidence of AKI through the entire data collection period was 27.6% (186 of 675). Among patients receiving caffeine, the odds of developing AKI were reduced by 44% during the data collection period (crude OR, 0.56; 95% CI, 0.38-0.84), an association that persisted after multivariable adjustment (adjusted OR, 0.27; 95% CI, 0.16-0.47). The NNE to prevent one case of AKI during the participants’ hospitalization (up to 120 days) was 4.4.
As summarized in eTable 4 and eTable 5 in the Supplement, exposure to caffeine remained associated with decreased frequency of AKI in both gestational age strata. In particular, an 87% decreased odds of early AKI was observed among extremely preterm neonates (adjusted OR, 0.13; 95% CI, 0.06-0.31; NNE, 2.2), and a 73% decreased odds of early AKI was observed for very preterm neonates (adjusted OR, 0.27; 95% CI, 0.13-0.56; NNE, 8.1). There was no statistical interaction between gestational age and caffeine administration, suggesting that there was no difference in the association of caffeine administration with early AKI by gestational age category. Similar, although slightly attenuated, associations were observed for all AKI, with an observed 76% decreased odds of any AKI among extremely preterm neonates (adjusted OR, 0.24; 95% CI, 0.10-0.58; NNE, 3.1) and a 68% decreased odds among very preterm neonates (adjusted OR, 0.32; 95% CI, 0.16-0.62; NNE, 8.0). As with early AKI, no statistical interaction was observed between gestational age and caffeine.
In this secondary analysis of the international, multicenter AWAKEN study cohort, preterm neonates who were exposed to caffeine were less likely to develop AKI. This association occurred despite the presence of traditional risk factors for AKI among neonates receiving caffeine (including younger gestational age, lower birth weight, and higher illness severity) and persisted even after multivariable adjustment. Neonates exposed to caffeine had an almost 3-fold reduction in the incidence of AKI and an 8-fold reduction in stage 3 AKI in the first week after birth, supporting the hypothesis that early exposure to caffeine is associated with a reduction in both AKI frequency and severity in preterm infants.
The field of neonatal AKI has undergone a renaissance, with numerous studies5,7,9,27-31 demonstrating that AKI in critically ill neonates is common and consistently associated with adverse outcomes. It is now acknowledged that preterm infants have a higher long-term risk of developing chronic kidney disease (CKD),32-40 and the findings of other studies33,41-43 have suggested that preterm infants who experience AKI are at particular risk of subsequent diagnosis of CKD. In light of the association of AKI with both short-term and long-term adverse outcomes, it is imperative to develop strategies to prevent or ameliorate AKI.
The results of this multicenter study confirm the association of caffeine administration with AKI in preterm neonates described in smaller studies, with an effect magnitude similar to that found previously in a single-center study22 of caffeine administration and AKI in VLBW neonates (NNE, 2.9 for both cohorts). However, while Carmody et al22 found that most AKI reduction after caffeine administration occurred in neonates with stage 1 AKI (with no association with more severe AKI stages), the findings of the present study suggest that the benefit of caffeine extends to more severe AKI.
In VLBW infants, caffeine use almost doubled between 1997 to 2010, from 40% to 70%.21 This dramatic increase coincides with clinical trials, such as the Caffeine for Apnea of Prematurity Trial,44,45 in which infants randomized to early treatment with caffeine were less likely to develop bronchopulmonary dysplasia. Over the same period, age at initiation of caffeine administration fell from a mean of 10 to 12 days after birth (median, 4-5 days) to a mean of 4 days (median, 1 day).21 In addition, the early use of caffeine has been associated with significant decreases in early-onset and late-onset sepsis, pulmonary interstitial emphysema, intraventricular hemorrhage, retinopathy of prematurity, duration of mechanical ventilation, bronchopulmonary dysplasia, and treatment of patent ductus arteriosus.21 Given these data, it is possible that decreased frequency of AKI among infants receiving caffeine is not mediated by any direct association of caffeine with kidney function but is instead conferred through benefits in neonatal respiratory status or hemodynamic stability.
There are several potential mechanisms of action through which caffeine and possibly other methylxanthines could directly reduce AKI. In investigations involving newborn rabbits exposed to caffeine or theophylline, Gouyon and Guignard46 reported increased renal blood flow, enhanced sodium excretion, and a higher glomerular filtration rate. A subsequent study47 by the same authors demonstrated that theophylline counteracted hypoxemia-induced renal hemodynamic changes by maintaining renal vascular resistance. Another potential mechanism of caffeine-mediated renal protection may involve attenuation of oxidative stress and injury on endoplasmic reticulum.48 Using a rodent hyperoxia model, Teng et al48 demonstrated that caffeine, at clinically appropriate doses, protected against hyperoxia-induced impairment of alveolar formation, improved radial alveolar count and secondary septation, increased vascularity, normalized several signaling pathways, maintained normal endoplasmic reticulum and mitochondrial structure, and decreased apoptosis. Whether any or all of these mechanisms could be relevant in the reduction of AKI seen in the present study requires further evaluation.
Although this study included a large, diverse sample enabling control for multiple potential confounders, there are several limitations. First, because this was an observational study, participants were not randomized to receive caffeine, and the indication for caffeine administration could not be ascertained. Second, although we created multivariable models to adjust for potential confounders, patients who received caffeine may nonetheless differ systematically from those who did not in unmeasured ways that could account for differences in AKI occurrence. Third, we were unable to evaluate a dose-dependent effect because medication dosages and systemic levels of caffeine were not collected in the AWAKEN study. Fourth, in this study, data collection was limited to a maximum of 120 days. Therefore, we could only assess short-term associations of caffeine administration with kidney function. Whether exposure to caffeine might confer long-term renal benefits was beyond the scope of this study. Fifth, there is also the possibility of misclassification bias because sCr and UOP values were not recorded every day on every infant. In addition, the definition of neonatal AKI used in this study does not take into account maternal sCr values or the possibility of misquantification of UOP. However, we believe that such misclassification, if present, would occur equally between both groups.
This large multicenter study found that caffeine administration in preterm infants is associated with reduced risk and severity of AKI. Given the established benefits, widespread use, and safety of early caffeine treatment in neonates younger than 28 weeks’ gestational age, it is no longer possible to ethically conduct a randomized clinical trial of caffeine vs placebo for protection against neonatal AKI. While these extremely preterm infants are at the highest risk of neonatal AKI, more mature neonates remain at risk: AKI occurred in almost 20% of the AWAKEN study participants born at 29 to 35 weeks’ gestation in the first week after birth. Because of the benefits and favorable adverse effect profile of caffeine, it may be reasonable to consider routine use of prophylactic caffeine in neonates of 28 to 32 weeks’ gestational age to prevent or reduce AKI, even when apnea of prematurity or the need for positive pressure respiratory support is absent. For extremely preterm neonates, evaluation of the optimal dose, duration, and timing of initiation of caffeine therapy to prevent and reduce the severity of AKI should be explored with a standard protocol for evaluating renal function and injury. Long-term outcomes of renal function and rates of CKD in those treated with caffeine are also needed to inform clinical practice.
Accepted for Publication: January 31, 2018.
Corresponding Author: Jennifer R. Charlton, MD, MSc, Division of Nephrology, Department of Pediatrics, University of Virginia, PO Box 800386, Charlottesville, VA 22908 (email@example.com).
Correction: This article was corrected on May 7, 2018, to fix omissions in the Group Information section of the end matter.
Published Online: April 2, 2018. doi:10.1001/jamapediatrics.2018.0322
Author Contributions: Dr Charlton had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Harer, Askenazi, Guillet, Selewski, Swanson, Charlton.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: All authors.
Critical revision of the manuscript for important intellectual content: Harer, Askenazi, Carmody, Griffin, Guillet, Selewski, Swanson, Charlton.
Statistical analysis: Askenazi, Boohaker, Griffin.
Administrative, technical, or material support: Askenazi, Charlton.
Study supervision: Harer, Askenazi, Charlton.
Conflict of Interest Disclosures: All authors reported no real or perceived conflicts of interest that could affect the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the manuscript for publication. For full disclosure, we provide the following additional list of authors’ other commitments and funding sources that are not directly related to this study. Dr Askenazi reported serving on the speaker board for Baxter and for the Acute Kidney Injury Foundation; he also reported receiving grant funding for studies not related to this work: grant R01 DK103608 from the National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases and grant R01 FD005092 from the National Institutes of Health/US Food and Drug Administration. Dr Guillet reported receiving grant funding unrelated to this study: grant CTSI UL1 TR002001 from the Patient-Centered Outcomes Research Institute. Dr Charlton reported being the co-owner of Sindri Technologies, LLC, which is not related to this study and reported receiving grants 3P50DK096373, R01DK110622, and R01DK111861 from the National Institutes of Health. No other disclosures were reported.
Funding/Support: Cincinnati Children’s Hospital Center for Acute Care Nephrology provided funding to create and maintain the Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates (AWAKEN) study Medidata Rave electronic database. The Pediatric and Infant Center for Acute Nephrology (PICAN) provided support for web meetings and for the Neonatal Kidney Collaborative (NKC) steering committee annual meeting at The University of Alabama at Birmingham (UAB), as well as support for 2 of the AWAKEN study investigators at UAB (Drs Askenazi and Griffin and Mr Boohaker). PICAN is part of the Department of Pediatrics at UAB and is funded by Children’s of Alabama hospital, UAB Department of Pediatrics, UAB School of Medicine, and UAB Center for Clinical and Translational Sciences (National Institutes of Health grant UL1TR001417). Finally, the AWAKEN study at The University of New Mexico was supported by the Clinical and Translational Science Center at The University of New Mexico (National Institutes of Health grant UL1TR001449) and by The University of Iowa Institute for Clinical and Translational Science (grant U54TR001356). The AWAKEN study investigators at the Canberra Hospital at the Australian National University Medical School were supported by the Canberra Hospital Private Practice Fund, and investigators at University of Virginia Children’s Hospital were supported by a 100 Women Who Care Grant from the 100 Women Charitable Foundation.
Role of the Funder/Sponsor: The funding sources for this study had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Group Information: The members of the NKC are listed below. The following individuals served as collaborators and site investigators for the AWAKEN study and deserve a PubMed citation. They collaborated in protocol development and review, local institutional review board submission, and data collection and participated in drafting or review of the manuscript; Namasivayam Ambalavanan, MD (Department of Pediatrics, The University of Alabama at Birmingham); Subrata Sarkar, MD (C. S. Mott Children’s Hospital, University of Michigan, Ann Arbor); Alison Kent, MD, and Jeffery Fletcher, PhD (Centenary Hospital for Women and Children, Canberra Hospital, Australian National University Medical School, Canberra); Carolyn L. Abitbol, MD, Marissa DeFreitas, MD, and Shahnaz Duara, MD (Holtz Children’s Hospital, University of Miami, Miami, Florida); Patrick Brophy, MD, Carl D’Angio, MD, Ayesa Mian, MD, and Erin Rademacher, MD (Golisano Children’s Hospital, University of Rochester, Rochester, New York); Maroun J. Mhanna, MD, Rupesh Raina, MD, and Deepak Kumar, MD (MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio); Ayse Akcan Arikan, MD, Christopher J. Rhee, MD (Texas Children’s Hospital, Baylor College of Medicine, Houston); Stuart L. Goldstein, MD, and Amy T. Nathan, MD (Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio); Juan C. Kupferman, MD, Alok Bhutada, MD, and Shantanu Rastogi, MD (Maimonides Medical Center, Brooklyn, New York); Elizabeth Bonachea, MD, John Mahan, MD, Arwa Nada, MBBCH, and Susan Ingraham, MD (Nationwide Children’s Hospital, Columbus, Ohio); Jennifer Jetton, MD, Tarah T. Colaizy, MD, and Jonathan M. Klein, MD (University of Iowa Children’s Hospital, Iowa City); F. Sessions Cole, MD, and T. Keefe Davis, MD (Washington University in St Louis, Missouri); Joshua Dower, BS, Lawrence Milner, MD, and Alexandra Smith, MD (Tufts University School of Medicine, Boston, Massachusetts); Kimberly Reidy, MD, and Frederick J. Kaskel, MD (The Children’s Hospital at Montefiore, Bronx, New York); Jason Gien, MD, Katja M. Gist, DO (University of Colorado, Children’s Hospital Colorado, Aurora); Mina H. Hanna, MD (University of Kentucky, Lexington); Craig S. Wong, MD, Catherine Joseph, MD, Tara DuPont, MD, Amy Staples, MD, and Robin Ohls, MD (University of New Mexico Health Sciences Center, Albuquerque); Surender Khokhar, MD (Apollo Cradle, Gurgaon, Haryana, India); Sofia Perazzo, MD, Patricio E. Ray, MD, and Mary Revenis, MD (Children’s National Medical Center, George Washington University School of Medicine and the Health Sciences, Washington, DC); Cherry Mammen, MD, and Anne Synnes, MDCM (British Columbia Children’s Hospital, Vancouver, Canada); Pia Wintermark, MD, and Michael Zappitelli, MD (Montreal Children’s Hospital, McGill University Health Centre, Montreal, Quebec, Canada); Sidharth K. Sethi, MD (Kidney and Urology Institute, Medanta the Medicity, Gurgaon, Haryana, India); Sanjay Wazir, MD (Neonatology, Cloudnine Hospital, Gurgaon, Haryana, India); Smriti Rohatgi, MD (Medanta the Medicity, Gurgaon, Haryana, India); Danielle E. Soranno, MD (University of Colorado, Children’s Hospital Colorado, Aurora); Aftab S. Chishti, MD (University of Kentucky, Lexington); and Robert Woroniecki, MD, and Shanty Sridhar, MD (Stony Brook School of Medicine, Stony Brook, New York).
Additional Contributions: We acknowledge the outstanding work of the following clinical research personnel and colleagues for their involvement in the AWAKEN study: Ariana Aimani, Samantha Kronish, Ana Palijan, MD, and Michael Pizzi (Montreal Children’s Hospital, McGill University Health Centre, Montreal, Quebec, Canada); Laila Ajour, BS, and Julia Wrona, BS (University of Colorado, Children’s Hospital Colorado, Aurora); Melissa Bowman, RN (University of Rochester, Rochester, New York); Teresa Cano, RN, Marta G. Galarza, MD, Wendy Glaberson, MD, Aura Arenas Morales, MD, and Denisse Cristina Pareja Valarezo, MD (Holtz Children’s Hospital, University of Miami, Miami, Florida); Sarah Cashman, BS, and Madeleine Stead, BS (University of Iowa Children’s Hospital, Iowa City); Jonathan Davis, MD, and Julie Nicoletta, MD (Floating Hospital for Children at Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts); Alanna DeMello (British Columbia Children’s Hospital, Vancouver, Canada); Lynn Dill, RN, and Emma Perez-Costas, PhD (The University of Alabama at Birmingham); Ellen Guthrie, RN (MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio); Nicholas L. Harris, BS, and Susan M. Hieber, MSQM (C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor); Katherine Huang and Rosa Waters (University of Virginia Children’s Hospital, Charlottesville); Judd Jacobs, Ryan Knox, BS, Hilary Pitner, MS, and Tara Terrell (Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio); Nilima Jawale, MD (Maimonides Medical Center, Brooklyn, New York); Emily Kane (Australian National University, Canberra); Vijay Kher, DM, and Puneet Sodhi, MBBS (Medanta Kidney Institute, Medanta the Medicity, Gurgaon, Haryana, India); Grace Mele (New York College of Osteopathic Medicine, Westbury); Patricia Mele, DNP (Stony Brook Children’s Hospital, Stony Brook, New York); Charity Njoku, Tennille Paulsen, and Sadia Zubair (Texas Children’s Hospital, Baylor College of Medicine, Houston); Emily Pao (University of Washington, Seattle Children’s Hospital, Seattle); Becky Selman, RN, and Michele Spear, CCRC (University of New Mexico Health Sciences Center, Albuquerque); Melissa Vega, PA-C (The Children’s Hospital at Montefiore, Bronx, New York); and Leslie Walther, RN (Washington University in St Louis, Missouri). No compensation was received.